[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"recurrent-or-metastatic-nasopharyngeal-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:recurrent-or-metastatic-nasopharyngeal-carcinoma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,47,75,102,135,156,178],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100637871","phase-2-sintilimab-combined-with-anlotinib-and-taxane-based-chemotherap-for-recurrentmetastatic-nasopharyngeal-carcinoma-100637871",false,"NCT07581821","Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent\u002FMetastatic Nasopharyngeal Carcinoma","A Prospective, Single-Arm Phase II Clinical Trial on the Efficacy and Safety of Sintilimab Combined With Anlotinib and Taxane-Based Chemotherapy in Previously Immunotherapy-Treated Recurrent\u002FMetastatic Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n1. Sign a written informed consent before implementing any trial-related procedures.\n2. Age is 18 or older and 65 or younger.\n3. Nasopharyngeal nonkeratinizing carcinoma (differentiated or undifferentiated, i.e. WHO type II or III) with histological or cytological evidence.\n4. Recurrent or metastatic nasopharyngeal carcinoma that has failed previous treatment with first-line platinum-containing standard regimens and\u002For second-line standard regimens.\n5. At least one measurable lesion according to the evaluation criteria for the efficacy of solid tumors (RECIST v1.1) is considered measurable if a lesion in a previously irradiated field is confirmed to have progressed;\n6. Participants with asymptomatic brain metastases or stable symptoms after local treatment may be enrolled, provided they meet the following criteria: 1) Measurable lesions outside the central nervous system; 2) No central nervous system symptoms or no symptom exacerbation within at least two weeks; 3) No need for glucocorticoid therapy, discontinued glucocorticoid treatment within seven days prior to initial administration, or stabilized glucocorticoid dosage within seven days prior to initial administration reduced to below 10 mg\u002Fday prednisone (or equivalent dose)\n7. Allow the subject to receive palliative radiotherapy (including cranial radiotherapy for symptomatic brain metastases), provided that the radiotherapy is completed at least 1 week prior to enrollment and that the toxicity associated with radiotherapy is restored to less than or equal to grade 1 (CTCAE 5.0, except for hair loss)\n8. ECOG score 0-1.\n9. Life expectancy\\> 3 months.\n10. If there is a risk of pregnancy, all subjects (male or female) should use contraception with an annual failure rate of less than 1% throughout the treatment period and for 120 days after the last study drug administration (or 180 days after the last study drug administration).\n\nExclusion Criteria:\n\n1. Diagnosis of a malignancy other than nasopharyngeal carcinoma within 5 years prior to the first dose (excluding cured basal cell carcinoma of the skin, squamous epithelial carcinoma of the skin, and\u002For cured carcinoma in situ that has been resected);\n2. Participants are currently enrolled in an interventional clinical study treatment or have received another investigational drug or used an investigational device within 4 weeks prior to the first dose\n3. Within 2 weeks before the first administration, patients received systemic treatment with traditional Chinese medicine or immunomodulatory drugs (including thymosin, interferon, interleukin, except for local use to control pleural effusion) for anti-tumor indications\n4. Active autoimmune diseases requiring systemic therapy (e.g., disease-modifying agents, glucocorticoids, or immunosuppressants) that occurred within 2 years prior to the first treatment. Replacement therapy (e.g., thyroid hormone, insulin, or physiologically administered glucocorticoids for adrenal or pituitary insufficiency) is not considered systemic therapy\n5. Study participants were receiving systemic glucocorticoid therapy (not including nasal, inhaled or other topical glucocorticoids) or any other form of immunosuppressive therapy within 7 days prior to the first study administration;\n6. The presence of clinically uncontrolled pleural\u002Fabdominal effusion (no drainage is required or the subject does not show significant increase in fluid over 3 days of discontinuation of drainage is eligible for enrollment)\n7. Known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation;\n8. Patients who are known to be allergic to the active ingredient or excipient of the study drug, sintilimab and anlotinib hydrochloride;\n9. Patients with multiple factors affecting oral medications (e.g., dysphagia, postgastrectomy, chronic diarrhea, intestinal obstruction, etc.);\n10. Cough, severe liver and kidney dysfunction;\n11. Not fully recovered from toxicity and\u002For complications caused by any intervention prior to starting treatment (i.e., ≤1 grade or baseline, excluding fatigue or hair loss)\n12. History of human immunodeficiency virus (HIV) infection (i.e., HIV 1\u002F2 antibody positive);\n13. Untreated active hepatitis B (defined as HBsAg-positive with HBV DNA copy count exceeding the upper limit of normal values in the laboratory department of the research center); Note: Eligible participants also include those meeting the following criteria: 1) HBV viral loa\n14. Active HCV-infected subjects (HCV antibody positive and HCV-RNA levels above the detection limit);\n15. Vaccinated with a live vaccine within 30 days prior to the first dose (Day 1 of Week 1); Note: Influenza vaccine injections for seasonal influenza are permitted within 30 days prior to the first dose; however, intranasal administration of live attenuated influenza vaccine is not permitted.\n16. Pregnant or lactating women;\n17. Participants with any severe or uncontrolled systemic diseases, such as: 1) significant and symptomatically severe abnormalities in rhythm, conduction, or morphology observed on resting electrocardiogram (e.g., complete left bundle branch block, second-degree or higher cardiac block, ventricular arrhythmias, or atrial fibrillation); 2) unstable angina, congestive heart failure, or chronic heart failure classified as NYHA Class II or higher; 3) myocardial infarction within six months prior to enrollment; 4) suboptimal blood pressure control (systolic\\>140 mmHg, diastolic\\>90 mmHg); 5) history of non-infectious pneumonia requiring glucocorticoid therapy within one year prior to first administration, or current clinical active interstitial lung disease; 6) active pulmonary tuberculosis; 7) active or uncontrolled infections requiring systemic treatment; 8) active diverticulitis, peritoneal abscess, or gastrointestinal obstruction; 9) liver disorders including cirrhosis, decompensated cirrhosis, acute\u002Fchronic active hepatitis; 10) poorly controlled diabetes (fasting blood glucose\\>10mmol\u002FL); 11) urine protein ≥++ detected in urinalysis with confirmed 24-hour protein\\>1.0 g; participants with psychiatric disorders and poor treatment compliance\n18. History or evidence of disease, abnormal treatment or laboratory test values that may interfere with the results of the trial and prevent the subject from participating in the study, or other conditions that the investigator deems unsuitable for enrollment, or other potential risks that the investigator deems unsuitable for participation in this study.","ALL","18 Years","65 Years",{"count":20,"type":21},33,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a prospective, single-arm Phase 2 study to evaluate the efficacy and safety of sintilimab combined with anlotinib and taxane-based chemotherapy in patients with recurrent (not unable to locally curative treatment) or metastatic NPC who failed at least first-line platinum-containing standard regimen and\u002For anti PD-1\u002FL1.",[27],"Recurrent or Metastatic Nasopharyngeal Carcinoma",[29,30,31,32,33],"Nasopharyngeal Carcinoma","Metastatic","Sintilimab","Anlotinib","taxane-based chemotherapy","RECRUITING","2026-05-06",{"date":37,"type":38},"2026-05-12","ACTUAL",{"date":40,"type":38},"2025-09-15",{"date":42,"type":21},"2028-12-31",{"name":44,"class":45},"Ming-Yuan Chen","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":46},"100591112","phase-3-a-study-of-mrg003-in-combination-with-pucotenlimab-versus-chemotherapy-in-the-treatment-of-patients-with-recurrent-or-metastatic-nasopharyngeal-carcinoma-100591112","NCT06976190","A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma","A Randomized, Open-label, Multi-center, Phase III Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma","Magic-C002","Inclusion Criteria:\n\n* Willing to sign the informed consent form and follow the requirements specified in the protocol.\n* Life expectancy ≥ 12 weeks.\n* Patients with histologically and cytologically confirmed recurrent or metastatic nasopharyngeal carcinoma (NPC) who have failed at least one line of prior systemic therapy.\n* Patients must have at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1).\n* The score of ECOG for performance status is 0 or 1.\n* No severe cardiac dysfunction, left ventricular ejection fraction (LVEF) ≥50%.\n* Organ functions and coagulation function must meet the basic requirements.\n* Patients with childbearing potential must use effective contraception during the treatment and for 6 months after the last dose of treatment.\n\nExclusion Criteria:\n\n* History of hypersensitivity to any component of the investigational product.\n* Received systemic chemotherapy, targeted therapy, biological therapy or immunotherapy for anti-tumor purpose, or major surgery within 3 weeks prior to the first dose of study treatment.\n* Received anti-infection therapy within 2 weeks prior to the randomization\n* Prior treatment with MMAE\u002FMMAF ADC drugs\n* Central nervous system metastasis.\n* Poorly controlled systemic diseases\n* Patients with poorly controlled heart diseases\n* Poorly controlled pleural and peritoneal effusion or pericardial effusion\n* ≥Grade 2 toxic reaction or abnormal value of laboratory test caused by previous anti-tumor treatment\n* Patients with prior ≥Grade 3 immuno-related adverse events (irAEs)\n* Any clinically significant arteriovenous bleeding, pulmonary embolism, or deep venous thrombosis occurred within 3 months\n* Received allogeneic tissue\u002Fsolid organ transplantation.\n* Inoculate live vaccine within 30 days before the first dose.\n* Patients with a positive serum pregnancy test or who are breast-feeding or who do not agree to take adequate contraceptive measures during the treatment and for 180 days after the last dose of study treatment.\n* History of other primary malignant tumor diseases.\n* Other situations that are not suitable to participate a clinical trial per investigator's judgement","75 Years",{"count":57,"type":21},446,[59],"PHASE3","This is a randomized, open-label, multi-center, phase III study to evaluate the efficacy and safety, and immunogenicity of MRG003 in combination with pucotenlimab in patients with recurrent or metastatic nasopharyngeal carcinoma.",[27],[63,64,29],"MRG003","Pucotenlimab","2026-01-16",{"date":67,"type":38},"2026-01-20",{"date":69,"type":38},"2025-05-06",{"date":71,"type":21},"2030-12",{"name":73,"class":74},"Shanghai Miracogen Inc.","INDUSTRY",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100612853","phase-1-a-study-of-yl201-in-combination-with-toripalimab-and-with-or-without-cisplatin-in-nasopharyngeal-carcinoma-100612853","NCT07258979","A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.","A Multicenter, Open-label, Phase Ib\u002FII Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 Combined With Toripalimab, With or Without Cisplatin, in Subjects With Recurrent or Metastatic Nasopharyngeal Carcinoma.","Inclusion Criteria:\n\n1. Voluntarily sign a written informed consent form (ICF).\n2. Aged ≥18 years and ≤75 years, male or female.\n3. ECOG performance status score of 0 or 1.\n4. Life expectancy ≥ 3 months.\n5. Disease and treatment history:\n\n   1. Histologically or cytologically confirmed recurrent or metastatic nasopharyngeal carcinoma that is not amenable to curative treatment.\n   2. Patients with newly diagnosed advanced nasopharyngeal carcinoma, categorized as Stage IV according to the 9th Edition of the American Joint Committee on Cancer (AJCC) Staging System; or those with recurrent nasopharyngeal carcinoma deemed unsuitable for local treatment\n   3. Metastatic or recurrent patients who are systemic treatment naïve.\n6. At least one measurable lesion according to RECIST v1.1.\n7. Adequate organ function.\n\nExclusion Criteria:\n\n1. History of other malignant tumors within 5 years prior to the first dose of study drug. Subjects who have been cured of other tumors by local therapy, such as basal cell carcinoma, squamous cell carcinoma of skin, bladder cancer in situ, cervical carcinoma in situ, or breast cancer in situ, are not excluded.\n2. Patients with brainstem metastases, leptomeningeal metastases, spinal cord metastases, or spinal cord compression.\n3. Patients with severe, uncontrolled cardiovascular disease.\n4. Patients with concomitant pulmonary disease resulting in clinically severe impairment of respiratory function.\n5. History of interstitial lung disease (ILD) or non-infectious pneumonitis requiring corticosteroid therapy, OR current ILD or non-infectious pneumonitis.\n6. Prior treatment with a B7-H3 targeted therapy (including antibodies, antibody-drug conjugates \\[ADCs\\], CAR-T cells, and other agents), or with a topoisomerase I inhibitor or an ADC containing a topoisomerase I inhibitor payload.\n7. Prior treatment with a PD-(L)1 inhibitor (including antibodies, antibody-drug conjugates \\[ADCs\\], CAR-T cells, and other agents).",{"count":83,"type":21},202,[85,24],"PHASE1","This is a multicenter, open-label, Phase Ib\u002FII study conducted in China to evaluate the safety, efficacy, and pharmacokinetic (PK) characteristics of YL201 combined with Toripalimab (doublet regimen) or YL201 combined with Toripalimab and Cisplatin (triplet regimen) in subjects with recurrent or metastatic nasopharyngeal carcinoma.",[27],[89,90,91],"YL201","recurrent or metastatic nasopharyngeal carcinoma","Toripalimab","2025-11-21",{"date":94,"type":38},"2025-12-02",{"date":96,"type":38},"2025-11-05",{"date":98,"type":21},"2028-05",{"name":100,"class":74},"MediLink Therapeutics (Suzhou) Co., Ltd.",20,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":134},"100598360","phase-2-combination-therapy-for-pd-1-resistant-recurrent-or-metastatic-nasopharyngeal-carcinoma-a-bayesian-adaptive-phase-ii-trial-100598360","NCT07070479","Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial","A Bayesian Adaptive Phase II Randomized Trial Comparing Ivonescimab, Ivonescimab Plus Nimotuzumab, Liposomal Mitoxantrone Plus Anti-PD-1 Antibody, and Liposomal Irinotecan Plus S-1 in Patients With PD-1-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n1. Histologically and\u002For cytologically confirmed recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (either differentiated or undifferentiated subtype, corresponding to WHO type II or III).\n2. Age between 18 and 70 years.\n3. Performance Status (PS) score of 0 or 1.\n4. Disease progression after prior platinum-based doublet chemotherapy.\n5. Received at least one line of systemic therapy previously. (Progression occurring during or within 6 months after definitive concurrent chemoradiotherapy, neoadjuvant\u002Fadjuvant therapy, or treatment completion may be counted as first-line treatment.)\n6. Resistance to anti-PD-1 antibody therapy (either combination or sequential), including primary or secondary resistance（PD-1 exposure must be at least 6 weeks.）\n7. At least one measurable lesion according to RECIST 1.1 criteria.\n8. All acute toxicities from prior anti-tumor therapies have resolved to grade ≤1 (per NCI-CTCAE v5.0) or meet the specified inclusion\u002Fexclusion thresholds. (Certain toxicities such as alopecia, hair color changes, nail changes, fatigue, etc., which do not pose safety risks, are exempt.)\n9. Adequate organ function:\n\n   Hematology: WBC ≥ 4000\u002FμL, absolute neutrophil count ≥ 2000\u002FμL, hemoglobin ≥ 9 g\u002FdL, platelets ≥ 100,000\u002FμL.\n\n   Liver function: Total bilirubin ≤ 1.5 × upper limit of normal (ULN) (patients with Gilbert's syndrome and bilirubin ≤ 3 × ULN are eligible); AST and ALT ≤ 3 × ULN; alkaline phosphatase ≤ 3 × ULN; albumin ≥ 3 g\u002FdL.\n\n   Coagulation: INR, prothrombin time (PT), or activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN.\n\n   Renal function: Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 60 mL\u002Fmin calculated by Cockcroft-Gault formula. Proteinuria: Urine protein\u002Fcreatinine ratio (UPC) \\\u003C 1.0. For UPC ≤ 0.5, no further testing is required; for UPC \\> 0.5, 24-hour urine protein must be \\\u003C 1000 mg for eligibility.\n10. Estimated life expectancy of at least 3 months.\n11. Signed informed consent and willingness and ability to comply with study visits, treatment plans, laboratory tests, and other study procedures.\n\nExclusion Criteria:\n\n1. Locoregional recurrent lesions that are amenable to definitive (curative) treatment, such as surgery.\n2. Prior treatment with any regimen included in the study protocol.\n3. Prior use of agents targeting the VEGF or VEGFR pathway.\n4. Diagnosis and\u002For treatment of another malignancy within the past 5 years, with the exception of adequately treated carcinoma in situ of the cervix, basal cell or squamous cell skin cancer, localized prostate cancer, or ductal carcinoma in situ.\n5. Receipt of surgery, chemotherapy, radiotherapy, immunotherapy, any investigational agent, or other anti-cancer therapy within 4 weeks prior to enrollment (or within 2 weeks for palliative radiotherapy).\n6. Tumor encasement of the internal carotid artery or evidence of nasopharyngeal necrosis observed on endoscopy prior to enrollment.\n7. Any significant bleeding event (≥ Grade 2, CTCAE v5.0) within 4 weeks prior to enrollment, or visible hemoptysis defined as ≥ 1\u002F2 teaspoon of fresh red blood or blood clots with little or no sputum. Recurrent positive fecal occult blood test (++ or more) during screening also leads to exclusion. (Patients with occasional blood-tinged sputum may be eligible.)\n8. Active peptic ulcers or gastrointestinal surgery within 1 month prior to enrollment; history within 6 months of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess, gastrointestinal hemorrhage, esophageal varices, or pathological fracture.\n9. Uncontrolled hypertension (systolic \\>140 mmHg or diastolic \\>90 mmHg) despite antihypertensive therapy; coronary artery disease ≥ Grade II; or any of the following within 6 months prior to enrollment: myocardial infarction, severe or unstable angina, NYHA class II or higher heart failure, sustained arrhythmia ≥ Grade 2 (including QTc \\>450 ms in males or \\>470 ms in females), atrial fibrillation of any grade, coronary or peripheral artery bypass grafting, symptomatic congestive heart failure, or cerebrovascular events (e.g., TIA or symptomatic pulmonary embolism). History of arterial thromboembolism or venous thromboembolism \\> Grade 3. (ST elevation ≥2 mm on ECG without clinical evidence of myocardial infarction or ischemia is not exclusionary.)\n10. History of bleeding diathesis, hemorrhagic disorders, or coagulopathy; current use of anticoagulants or antiplatelet agents including warfarin, heparin, aspirin \\>325 mg\u002Fday, ticlopidine, clopidogrel, or cilostazol, unless discontinued ≥10 days prior to first dose and coagulation parameters meet inclusion criteria.\n11. Severe infection requiring intravenous antibiotics, antifungals, or antivirals within 4 weeks prior to the first dose, or unexplained fever \\>38.5°C within 7 days prior to the first dose; baseline WBC \\>15 × 10⁹\u002FL.\n12. Known hypersensitivity to study drugs or excipients, or a history of severe hypersensitivity reactions such as generalized rash\u002Ferythema, hypotension, bronchospasm, angioedema, or anaphylaxis.\n13. Conditions that may affect oral drug absorption, including dysphagia, nausea\u002Fvomiting, chronic diarrhea, or bowel obstruction.\n14. Ongoing treatment with immunosuppressants or systemic corticosteroids (\\>10 mg\u002Fday prednisone or equivalent) within 2 weeks prior to the first dose.\n15. Presence of any active autoimmune disease or a history of autoimmune diseases likely to recur (including but not limited to interstitial pneumonitis, uveitis, colitis, hepatitis, hypophysitis, nephritis, hyperthyroidism, hypothyroidism). Exceptions include vitiligo and childhood asthma now in complete remission. Patients with asthma requiring bronchodilator therapy are excluded.\n16. History of acute exacerbation of chronic obstructive pulmonary disease or other respiratory disease requiring hospitalization within 1 month prior to enrollment; patients with active tuberculosis or those who received anti-TB therapy within 1 year prior to screening.\n17. HIV positive; or positive HBsAg with quantifiable HBV DNA ≥1000 cps\u002FmL; or positive anti-HCV antibody.\n18. Receipt of live vaccines within 4 weeks prior to first dose or anticipated during the study period.\n19. Positive pregnancy test or currently breastfeeding.\n20. Women of childbearing potential or sexually active men who are unwilling or unable to use medically accepted methods of contraception during the study period.\n21. Any condition, as determined by the investigator, that may interfere with the study results or patient safety, such as substance abuse, serious physical or mental illness requiring concurrent treatment, significant laboratory abnormalities, or adverse social\u002Ffamily circumstances.","70 Years",{"count":111,"type":21},208,[24],"This is a prospective, Bayesian adaptive, phase II clinical trial designed to evaluate the safety and efficacy of four treatment regimens in patients with recurrent (unamenable to local therapy) or metastatic nasopharyngeal carcinoma (NPC) who have failed after at least one prior platinum-containing standard regimen and anti-PD-1\u002FPD-L1 therapy.\n\nThe four treatment arms include:\n\n1. Ivonescimab monotherapy,\n2. Ivonescimab combined with nimotuzumab,\n3. Liposomal mitoxantrone plus anti-PD-1 antibody, and\n4. Liposomal irinotecan plus S-1.",[27],[116,117,118,119,120,121,122,123,124,125],"nasopharyngeal carcinoma","Recurrent","metastatic","PD-1 resistance","Bayesian adaptive design","Ivonescimab","Nimotuzumab","Liposomal mitoxantrone","Liposomal irinotecan","S-1","2025-09-12",{"date":128,"type":38},"2025-09-18",{"date":130,"type":38},"2025-06-24",{"date":132,"type":21},"2028-01-30",{"name":44,"class":45},6,{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":109,"enrollmentInfo":142,"targetDuration":4,"studyType":22,"phases":144,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":46},"100566631","phase-2-irinotecan-liposome-combined-with-s-1-in-pd-1l1-inhibitor-refractory-recurrent-or-metastatic-npc-100566631","NCT06657690","Irinotecan Liposome Combined with S-1 in PD-1\u002FL1 Inhibitor Refractory Recurrent or Metastatic NPC","The Efficacy and Safety of Irinotecan Liposome Combined with S-1 in PD-1\u002FL1 Inhibitor Refractory Recurrent or Metastatic Nasopharyngeal Carcinoma: a Prospective, Single-arm Phase 2 Study","Inclusion Criteria:\n\n* 1\\. Willing to participate in the study, sign the informed consent form (ICF), and comply with study plan visits, treatment plans, laboratory tests, and other study procedures.\n\n  2\\. Age ≥ 18 years. 3. Nasopharyngeal carcinoma confirmed by histopathology (differentiated or undifferentiated non-keratinous carcinoma).\n\n  4\\. Recurrent or metastatic nasopharyngeal carcinoma that has failed at least first-line anti-PD-1\u002FL1, whether or not combined with platinum-containing standard regimen (Anti PD-1\u002FL1 exposure at least 6 weeks, and the protocol used at the time of enrollment in this study meets one of the following two points: (1) Relapse during adjuvant therapy after radiotherapy, or relapse within 6 months after the end of treatment; (2) First-line treatment phase, progression during anti-PD-1\u002FL1 treatment, or progression within 3 months after the end of anti-PD-1\u002FL1).\n\n  5\\. Recurrent or metastatic nasopharyngeal carcinoma that is unable to local curative treatment (surgery or radiotherapy).\n\n  6\\. At least one measurable lesion according to RECIST 1.1 criteria (the spiral CT scan diameter of the measurable lesion is ≥ 10 mm or the short diameter of the enlarged lymph node is ≥15mm ); lesions that have undergone local treatment can be selected as target lesions if there is clear evidence of significant progress compared to the end of treatment.\n\n  7\\. ECOG PS (Eastern Cooperative Oncology Group Performance Status) score 0-1. Expected survival ≥3 months.\n\n  8\\. Adequate main organ function: a. Liver function: AST and ALT ≤ 2.5 times ULN, bilirubin ≤ 1.5 times the upper limit of normal (ULN) (patients with known Gilbert disease and serum bilirubin level ≤ 3 times ULN could be enrolled; patients with liver metastasis, ≤ 5 times ULN); b. Renal function: serum creatinine ≤ 1.5 ULN or creatinine clearance ≥ 30 mL\u002Fmin according to Cockcroft-Gault formula; c. Hematology: neutrophil absolute value (ANC) ≥1.0×10\\^9\u002FL, hemoglobin (Hb) ≥ 9.0 g\u002FdL, platelets ≥ 100×10\\^9\u002FL.\n\nExclusion Criteria:\n\n* 1\\. Severe allergy to Irinotecan liposome (such as systemic rash\u002Ferythema hypotension, bronchospasm, angioedema, or anaphylaxis).\n\n  2.CYP3A4 strong inducer used within 2 weeks, or CYP3A4\u002FUGT1A1 strong suppressor used within 1 week prior to initial administration.\n\n  3\\. Estimated survival \\\u003C 3 months. 4.HBsAg positive and HBV DNA copy number positive (quantitative detection ≥2000 IU\u002Fml); Chronic hepatitis C blood screening positive (HCV antibody positive). Patients with normal liver function and concurrent antiviral therapy were determined by the investigator to be eligible for enrollment.\n\n  5\\. HIV-positive people. 6. Patients with active bacterial infection, fungal infection, viral infection, or interstitial pneumonia require systemic treatment within 1 week prior to first administration.\n\n  7\\. Received chemotherapy, targeted therapy, immunotherapy, or any investigational drug or other antitumor therapy within 4 weeks or 5 half-lives before first administration (whichever is shorter but at least 2 weeks).\n\n  8\\. Received Chinese medicine with antitumor activity within 14 days before administration; Received other investigational drugs within 4 weeks prior to initial dosing.\n\n  9\\. Patients who had undergone major surgery within 3 months prior to initial dosing or planned to undergo major surgery during the study period.\n\n  10\\. Severe embolic events, such as cerebrovascular accidents (including transient ischemic attacks) and pulmonary embolism, occurred in the 6 months before screening.\n\n  11\\. Diagnosed and\u002For treated with other malignancies within 2 years before initial administration (except for curable malignancies that have undergone radical treatment, such as skin basal cell, carcinoma in situ of the cervix, papillary thyroid cancer, etc).\n\n  12\\. Severe cardiovascular disease during the 6 months before enrollment, including but not limited to the following: Acute myocardial infarction, unstable angina pectoris, coronary angioplasty or stenting, deep vein thrombosis, stroke; New York Heart Association Class III or IV congestive heart failure or left ventricular ejection fraction (LVEF) \\\u003C 50%; According to the investigator's assessment, clinically significant abnormal electrocardiogram (ECG) at the time of screening.\n\n  13\\. Pregnant or lactating women. 14. Serious dysfunction of heart, lung, liver, kidney, and other vital organs; serious and\u002For uncontrollable disease that may affect the patient's participation in the study (including, but not limited to, uncontrolled diabetes, life-threatening autoimmune and bleeding disorders, substance abuse, neurological disorders, etc.).\n\n  15\\. Other situations that the investigator determines to be inappropriate for participation.",{"count":143,"type":21},56,[24],"This is a prospective, single-arm Phase 2 study to evaluate the efficacy and safety of Irinotecan Liposome injection combined with S-1 in patients with recurrent (unable to local curative treatment) or metastatic NPC who failed at least first-line anti-PD-1\u002FL1.",[27],"2025-01-09",{"date":149,"type":38},"2025-01-10",{"date":151,"type":38},"2024-11-01",{"date":153,"type":21},"2027-10-31",{"name":155,"class":45},"Sun Yat-sen University",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":109,"enrollmentInfo":163,"targetDuration":4,"studyType":22,"phases":165,"briefSummary":166,"conditions":167,"keywords":168,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":46},"100552409","phase-2-clinical-study-of-mitoxantrone-hydrochloride-liposome-combined-with-pd-1-blockade-in-recurrent-or-metastatic-npc-100552409","NCT06472713","Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC","A Prospective, Single-arm Phase 2 Study Evaluating the Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection Combined with PD-1 Blockade in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n1. Willing to participate in the study, sign the informed consent form (ICF), and comply with study plan visits, treatment plans, laboratory tests, and other study procedures.\n2. Nasopharyngeal carcinoma confirmed by histopathology (differentiated or undifferentiated non-keratinous carcinoma).\n3. Age ≥ 18 \\& ≤ 70 years.\n4. PS (Performance Status) score 0-1.\n5. Recurrent or metastatic nasopharyngeal carcinoma that has failed first-line platinum-containing standard regimen and\u002For second-line standard regimen failure.\n6. Previously received at least one line of systemic therapy. (Progression after radical concurrent chemoradiotherapy, during neoadjuvant or adjuvant therapy, or within 6 months after the end of treatment can be recorded as 1-line therapy).\n7. Recurrent or metastatic nasopharyngeal carcinoma that has failed anti PD-1\u002FL1: anti PD-1\u002FL1 exposure at least 6 weeks, and the protocol used at the time of enrollment in this study meets one of the following two points: (1) Relapse during adjuvant therapy after radiotherapy, or relapse within 6 months after the end of treatment; (2) First-line treatment phase, progression during anti PD-1\u002FL1 treatment, or progression within 3 months after the end of anti PD-1\u002FL1 (whether combined with chemotherapy\u002Ftargeting drugs);\n8. At least one measurable lesion according to RECIST 1.1 criteria (the spiral CT scan diameter of the measurable lesion is ≥ 10 mm or the short diameter of the enlarged lymph node is ≥15mm ); lesions that have undergone local treatment can be selected as target lesions if there is clear evidence of significant progress compared to the end of treatment.\n9. All acute toxicities of previous antitumor therapy have returned to ≤ grade 1 (according to NCI-CTCAE v5.0) or reached the level specified in the inclusion\u002Fexclusion criteria. (Except for partial toxicity, such as alopecia, hair color change, nail change, fatigue, etc., which do not pose safety risks to subjects).\n10. Adequate main organ function. a. Hematology: neutrophil absolute value (ANC) ≥1.5×10\\^9\u002FL, hemoglobin (Hb) ≥ 9.0 g\u002FdL, platelets ≥ 100×10\\^9\u002FL; b. Liver function: bilirubin ≤ 1.5 times the upper limit of normal (ULN) (patients with known Gilbert disease and serum bilirubin level ≤ 3 times ULN could be enrolled; patients with liver metastasis, ≤ 5 times ULN), AST and ALT ≤ 3 times ULN, and alkaline phosphatase ≤ 3 times ULN; Albumin ≥ 3 g\u002FdL; c. International Normalized ratio (INR) or prothrombin time (PT) or activated partial thromboplastin time (aPTT) ≤ 1.5 times; d. Renal function: serum creatinine ≤ 1.5 ULN or creatinine clearance ≥ 60 mL\u002Fmin according to Cockcroft-Gault formula; e. Proteinuria: urinary protein\u002Fcreatinine ratio (UPC ratio) \\\u003C 1.0. If the UPC ratio is less than or equal to 0.5, no further check is required. Patients with UPC ratio \\> 0.5 and those with 24-hour urinary protein \\\u003C 1000 mg could be enrolled; f. Note: The UPC ratio of random urine is a quantitative estimate of 24-hour urinary protein, and the two have a good correlation. UPC ratio can be calculated using the following formula: (a) Urinary protein\u002Furinary creatinine (if both protein and creatinine are mg\u002FdL); (b) (urinary protein)\\*0.088\u002F urinary creatinine (if urinary creatinine is mmol\u002FL).\n11. Survival is expected to be ≥ 3 months.\n12. Female subjects with negative blood human chorionic gonadotropin (HCG) (except for menopause and hysterectomy), female subjects of reproductive age and their partners using effective contraception during the trial period and within 6 months after the end of the last dose (e.g. Combined hormones \\[containing estrogen and progesterone combined to inhibit ovulation, progesterone contraception combined to inhibit ovulation, IUD, intrauterine hormone release system, bilateral tubal ligation, vasectomy, abstinence from sex, etc.).\n13. Male patients and their partners agree to use one of the contraceptive measures described in Article 9.\n\nExclusion Criteria:\n\n1. Recurrent lesions in local areas suitable for radical method (surgery) treatment.\n2. Severe allergy to mitoxantrone or liposome (such as systemic rash\u002Ferythema hypotension, bronchospasm, angioedema, or anaphylaxis).\n3. Prior treatment with doxorubicin or other anthracyclines and the cumulative doxorubicin doses greater than 350 mg\u002Fm\\^2 (anthracycline equivalent: 1 mg doxorubicin = 2 mg epirubicin = 2 mg daunorubicin = 0.5 mg normethoxydaunorubicin = 0.45 mg mitoxantrone).\n4. Estimated survival \\\u003C 3 months.\n5. Diagnosed and\u002For treated with other malignancies within 5 years prior to initial administration. (except for cervical cancer, skin basal cell or squamous cell carcinoma, localized prostate cancer, and ductal carcinoma in situ after radical treatment).\n6. Received surgery, chemotherapy, radiotherapy, immunotherapy, or any investigational drug or other antitumor therapy within the 4 weeks prior to initial administration (less than 2 weeks after palliative radiotherapy).\n7. Patients with hypertension who cannot be reduced to the normal range by antihypertensive drugs (systolic blood pressure \\> 140 mmHg\u002F diastolic blood pressure \\> 90 mmHg); Have ≥ grade II coronary heart disease; Any of the following conditions occurred during the first 6 months of enrollment: Myocardial infarction, severe\u002Funstable angina pectoris, NYHAII grade or higher cardiac insufficiency, grade 2 or higher persistent arrhythmias (including prolonged QTc interval \\> 450ms in men), Women \\> 470ms), any grade of atrial fibrillation, coronary\u002Fperipheral artery bypass grafting, symptomatic congestive heart failure, or cerebrovascular accident (including transient ischemic attack or symptomatic pulmonary embolism); The ejection fraction of the heart is below 50% or below the lower limit of the range of laboratory tests at the study center. Patients with a history of arterial thromboembolism events and venous thromboembolism \\> grade 3. (Patients with S-T elevation ≥ 2mm on the ECG may be enrolled if they do not show signs of recent myocardial infarction or ischemia) (according to NCI-CTCAE v5.0).\n8. Severe infection (such as intravenous antibiotics, antifungals, or antivirals as required by clinical practice) during the 4 weeks prior to the first dose, or any unexplained fever \\>38.5 ° C during the screening period \u002F 7 days prior to the first dose, or white blood cell count \\>15×109\u002FL at baseline.\n9. Immunosuppressants, or systemic hormone therapy (dose \\>10mg\u002F day of prednisone or other therapeutic hormone) are being used for the purpose and continue to be used within 2 weeks before the first dose.\n10. The subject has any active autoimmune disease or history of autoimmune disease (including but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, pituitaritis, nephritis, hyperthyroidism, hypothyroidism; Patients with vitiligo or who had complete remission of asthma in childhood and did not require any intervention as adults were included; Patients with asthma requiring medical intervention with bronchodilators were not included).\n11. Exacerbations of COPD or other respiratory diseases requiring hospitalization within 1 month prior to registration.Patients with active tuberculosis (TB) who are receiving anti-TB therapy or have received anti-TB therapy within 1 year prior to screening.\n12. HIV-positive people; HBsAg positive and HBV DNA copy number positive (quantitative detection ≥1000 cps\u002Fml); Chronic hepatitis C blood screening positive (HCV antibody positive).\n13. Live vaccine was administered within 4 weeks before the first dose or possibly during the study period.\n14. Pregnant or lactating women.\n15. Women with reproductive potential and sexually active men who are unwilling\u002Funable to use medically acceptable forms of contraception.\n16. Have any serious and\u002For uncontrollable medical conditions that, as determined by the investigator, may affect the patient's participation in the study, such as alcoholism, drug abuse, other serious diseases (including mental illness) that require combined treatment, serious laboratory abnormalities, and family or social factors that affect the safety of the patient.\n17. Other situations that the investigator determines to be inappropriate for participation.",{"count":164,"type":21},32,[24],"This is a prospective, single-arm Phase 2 study to evaluate the efficacy and safety of mitoxantrone hydrochloride liposome injection combined with PD-1 blockade in patients with recurrent (not unable to locally curative treatment) or metastatic NPC who failed at least first-line platinum-containing standard regimen and\u002For anti PD-1\u002FL1.",[27],[29,117,30,169,170],"Mitoxantrone Hydrochloride Liposome","PD-1 Blockade",{"date":172,"type":38},"2025-01-13",{"date":174,"type":38},"2024-07-20",{"date":176,"type":21},"2027-09-30",{"name":44,"class":45},{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":184,"targetDuration":4,"studyType":22,"phases":186,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":46},"100534651","phase-2-a-multi-center-randomized-double-blind-phase-iiiii-clinical-trial-of-ak104-or-placebo-in-combination-with-chemotherapy-as-second-line-or-more-lines-for-recurrent-or-metastatic-nasopharyngeal-carcinoma-npc-100534651","NCT06241599","A Multi-center, Randomized, Double-blind, Phase II\u002FIII Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)","Inclusion Criteria:\n\n1\\. Age ≥18 years and ≤75 years; 2. Non-keratinized differentiated or undifferentiated nasopharyngeal carcinoma confirmed by pathology; 3. For patients with recurrent and metastatic nasopharyngeal carcinoma who are not eligible for local treatment and meet the definition of the staging system (8th edition) of the International Union against Cancer and the American Joint Committee on Cancer (UICC\u002FAJCC), local treatment mainly refers to measures related to anti-tumor treatment, including surgery, radiofrequency ablation, transhepatic arterial chemoembolization (TACE), radiotherapy (except for patients with bone metastasis). A locally appropriate dose of radiotherapeutic therapy for symptomatic relief) 4. Patients with nasopharyngeal carcinoma recurrence and metastasis who failed first-line treatment; 5.ECOG performance score 0 or 1; 6. There is at least one measurable lesion according to the RECIST1.1 evaluation criteria, and a lesion that has previously received, for example, radiation therapy can be considered a target lesion if there is objective evidence of disease progression. 7. Patients are required to provide tissue samples within three years prior to enrollment; 8. Expected survival ≥3 months; 9. The functions of vital organs meet the following requirements (no blood components, cell growth factors, whitening drugs, thrombocytophytics, or anemia correction drugs are allowed within 14 days before screening) : · Neutrophil absolute count (ANC) ≥1.5×109\u002FL· Platelets ≥100×109\u002FL; · Hemoglobin ≥8.0g\u002Fdl (note: Hemoglobin ≥8.0g\u002Fdl through blood transfusion or other intervention is acceptable); · Serum albumin ≥2.8g\u002FdL; · Bilirubin ≤ 1.5x ULN, ALT and AST≤ 1.5x ULN; If there is liver metastasis, ALT and AST are less than 5 times ULN. Creatinine clearance ≥50mL\u002Fmin (using the standard CockcroftGault formula, see Annex II); 10. Women of reproductive age who have an unsterilized sexual partner should use at least one highly effective form of birth control; 11. Unsterilized men with a partner of childbearing age must use a highly effective form of birth control from day 1 to day 120 of the last use of the study drug; 12. Informed consent has been signed.\n\nExclusion Criteria:\n\n1\\. Previous history of allergy to 5-Fu, cisplatin, gemcitabine, other monoclonal antibodies or any component of CTLA-4 and PD1 bispecial antibodies; In the past, CTLA-4 and PD1-specific antibody therapy were used simultaneously. 2. Had major surgery other than diagnosis of nasopharyngeal cancer within 28 days prior to randomization or was expected to require major surgery during the study period; 3. The subject has any active autoimmune disease or a history of autoimmune disease (e.g., but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism; Subjects with vitiligo or asthma that has been in complete remission in childhood can be adults without any intervention.Patients with asthma requiring medical intervention with bronchodilators were not included); 4. Subjects were taking immunosuppressants, or systemic, or absorbable local hormone therapy for immunosuppressive purposes (doses \\>10mg\u002F day of prednisone or other therapeutic hormones) and continued to use within 2 weeks prior to enrollment; 5. Known subject is previously allergic to macromolecular protein preparation ingredients; 6. The subject has clinically symptomatic central nervous system metastases (e.g. brain edema, need for hormonal intervention, or progression of brain metastases); Other aggressive malignancies within 7.5 years, except locally curable (appearing to cure) malignancies such as basal or squamous cell carcinoma of the skin, superficial cancers of the bladder, cervix and breast in situ; 8. Active autoimmune disease requiring systemic treatment within the last two years, except vitiligo, alopecia, Grave disease, psoriasis or eczema that did not require systemic treatment within the last two years, hypothyroidism requiring stable hormone replacement therapy only (due to autoimmune thyroiditis), type 1 diabetes requiring stable dose insulin replacement therapy only; Childhood asthma that has been completely cured in adulthood without intervention or primary disease that does not recur unless stimulated by external factors; 9. Active or previous inflammatory bowel disease (such as Crohn's disease, ulcerative colitis, or chronic diarrhea); 10. Systemic glucocorticoid therapy (dose equivalent to 10mg\u002F day of prednisone) or other immunosuppressants are required within the first seven days of initial administration of the investigational drug. 11. Having allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation; 12. Gastrointestinal perforation or fistula within the first six months of enrollment; 13. There were necrotic foci within the first four weeks of enrollment that researchers thought might be a potential source of major bleeding;14. History of interstitial pneumonia; 15. History of active tuberculosis; 16. Serious infections, including but not limited to complications requiring hospitalization, sepsis, or severe pneumonia, occur within four weeks prior to the first application of the investigational drug; 17. Active infections that require systematic treatment; 18. Untreated chronic hepatitis B or chronic HBVDNA≥1000IU\u002Fml or active hepatitis C. Non-active HBsAg carriers, stable hepatitis B after treatment (HBVDNA \\\u003C 1000IU\u002Fml) and cured hepatitis C can be included. Patients who are positive for HCV antibodies can only be enrolled if they test negative for HCVRNA. 19. History of major surgery within 30 days before the first application of the investigational drug; 20. There is meningeal metastasis or active brain metastasis; 21. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage; 22. Toxicity problems unresolved at the time of previous antitumor therapy, defined as unresolved to level 0 or 1 of NCICTCAEv5.0, or levels specified in the inclusion\u002Fexclusion criteria, except hair loss. 23. Live attenuated vaccines were administered within 30 days prior to the first application of the investigational drug, or live attenuated vaccines were planned to be administered during the study period. 24. Known history of severe allergy to other monoclonal antibodies; 25. Pregnant or lactating women; 26. Have clinical symptoms or diseases of heart that are not well controlled, such as: ① heart failure of NYHA2 or above; ② Unstable angina pectoris; ③ Myocardial infarction occurred within 1 year; Patients with clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention; 27. Subjects had an active infection or unexplained fever \\>38.5 degrees during screening or prior to initial dosing (as determined by the investigator, subjectsFever due to tumor can be included in the group); •28. Allergic to AK104 ingredients; 29. The subject has a known history of psychotropic substance abuse, alcohol abuse, or drug use; 30. According to the investigator's judgment, the subjects have other factors that may lead to the forced termination of the study, such as other serious illnesses (including mental illness) requiring combined treatment, serious abnormalities in laboratory tests, and family or social factors that may affect the safety of the subjects, or the collection of test data and samples.",{"count":185,"type":21},300,[24,59],"To compare whether AK104 combined with GP or PFLL can improve survival benefit, safety and tolerability in nasopharyngeal carcinoma patients who have failed first-line treatment; To compare the survival benefits of GP or GFLL treatment in nasopharyngeal carcinoma patients who had failed first-line therapy; To compare the survival benefits of GP or GFLL combined with AK104 in patients with nasopharyngeal carcinoma who had failed first-line therapy.",[27],"2024-01-28",{"date":191,"type":38},"2024-02-05",{"date":193,"type":21},"2024-02-01",{"date":195,"type":21},"2029-02-01",{"name":155,"class":45}]